Karen Ann Norris

US Patent:

20130315857, Nov 28, 2013

Filed:

Aug 5, 2013

Appl. No.:

13/959691

Inventors:

KAREN NORRIS - PITTSBURGH PA, US
HEATHER KLING - PITTSBURGH PA, US

Assignee:

BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE - BATON ROUGE LA
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - PITTSBURGH PA

International Classification:

C12N 9/58
A61K 38/19
A61K 39/00

US Classification:

424 851, 435223, 536 232, 4241851

Abstract:

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

US Patent:

20220401533, Dec 22, 2022

Filed:

Nov 12, 2020

Appl. No.:

17/776938

Inventors:

- Athens GA, US
Whitney RABACAL - Athens GA, US
Karen NORRIS - Athens GA, US

Assignee:

University of Georgia Research Foundation, Inc. - Athens GA

International Classification:

A61K 39/00
C07K 16/14
C07K 14/38
A61P 31/10

Abstract:

The invention generally provides methods of treating or preventing aspergillosis disease and/or its symptoms associated with infection by the pathogenic fungus. The methods involve administering an Kexin peptide, or a composition comprising an peptide, to a mammalian subject in need thereof, such as a subject afflicted with , or a subject susceptible to or at risk of infection by and ensuing aspergillosis disease. In some aspects, the Kexin peptide is an Kexin peptide. In some aspects, the mammalian subject is a human patient. In some aspects, the patient is immunosuppressed or immunocompromised. The Kexin peptide as immunogen or vaccine generates a potent and robust immune response, e.g., antibody response, in the immunized subject. The methods afford therapeutic and protective treatment against aspergillosis and its symptoms, as well as a reduction in the severity of aspergillosis in the treated subjects.

US Patent:

20210145948, May 20, 2021

Filed:

May 13, 2020

Appl. No.:

15/931213

Inventors:

- Pittsburgh PA, US
- Baton Rouge LA, US
Karen Norris - Pittsburgh PA, US
Heather Kling - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - PITTSBURGH PA
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College - Baton Rouge LA

International Classification:

A61K 39/00
C12N 9/58
A61K 38/19
C07K 14/705
C12N 9/60

Abstract:

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

US Patent:

20180318406, Nov 8, 2018

Filed:

Jul 13, 2018

Appl. No.:

16/035319

Inventors:

- PITTSBURGH PA, US
- Baton Rouge LA, US
Karen Norris - Pittsburgh PA, US
Heather Kling - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - PITTSBURGH PA
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College - Baton Rouge LA

International Classification:

A61K 39/00
A61K 38/19
C07K 14/705
C12N 9/58
C12N 9/60

Abstract:

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

US Patent:

20170173127, Jun 22, 2017

Filed:

Feb 27, 2017

Appl. No.:

15/443976

Inventors:

- Pittsburgh PA, US
- BATON ROUGE LA, US
Karen Norris - Pittsburgh PA, US
Heather Kling - Pittsburgh PA, US

Assignee:

University of Pittsburgh - of the Commonwealth System of Higher Education - Pittsburgh PA
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College - BATON ROUGE LA

International Classification:

A61K 39/00
C07K 14/705
C12N 9/60

Abstract:

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as spp. The vaccine may be used to prevent or to treat fimgal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.